Board Members
Joseph Leyba, PharmD, RPh – President
Kristen Snair, CPhT – Vice President
Lorri Walmsley, RPh – Member
Ted Tong, RPh – Member
Kevin Dang, PharmD, RPh – Member
Mohammad (Mo) Safari, RPh – Member
Michael Blaire, RPh – Member
Kyra Locnikar – Member (Public)
Reuben Minkus – Member (Public)

The Board Is on Facebook
Follow the Arizona State Board of Pharmacy for the latest news and updates at https://www.facebook.com/arizona-state-board-of-pharmacy-396869467321193.

Update Your Profile
In an effort to communicate more effectively with licensees and permittees, the Board has noticed that contact information in its system is not current and up to date. Please use your online profile to update your contact information.

Disciplinary Actions and Updates
Pharmacists
Damian John Hohensee (S013084) – Amended decision and order. License revoked.
Anne M. Feeney (S013068) – Consent agreement for civil penalty. The consent agreement includes a $1,000 civil penalty.
Robert D. Ferguson (S015380) – Consent agreement for civil penalty. The consent agreement includes a $300 civil penalty.
Jay Amin (S021262) – Consent agreement for civil penalty, continuing education (CE), and audit. The consent agreement includes an $850 civil penalty, 45 hours of CE required during the next renewal period, and a mandatory audit.
Andrew Jonathan Kolp (S016676) – Consent agreement for civil penalty, CE, and audit. The consent agreement includes a $150 civil penalty, 45 hours of CE required during the next renewal period, and a mandatory audit.
Robert Wilcox (S012472) – Consent agreement and order for probation and monitoring. License placed on probation for a minimum of two years.
James Brian Lopresti (S022015) – Consent agreement for CE (disciplinary). The consent agreement includes three CE in patient safety.
Mark E. Alden (S007878) – Consent agreement for civil penalty, CE, and audit. The consent agreement includes a $1,000 civil penalty, 45 hours of CE required during the next renewal period, and a mandatory audit.

Joyce Dee Vandersloot (S014870) – Consent agreement and order for probation of license. License placed on probation for a minimum of five years.
Nicholas Bradford Tracy (S022054) – Consent agreement for CE (disciplinary). Consent agreement for three hours of CE in law.
Brian J. Wambold (S013902) – Consent agreement and order for suspension and probation of license. Six-month suspension from December 14, 2018. Probation for a minimum of four years and six months after suspension.
Robin Suzette O’NeLe (S014246) – Findings of fact, conclusions of law, and order for revocation. License revoked.
William N. Clark (S013729) – Consent agreement and order for surrender. License voluntarily surrendered.
Mark Kenneth Ziegler (S018989) – Consent agreement and order for suspension and probation. Six-month suspension followed by four years and six months on probation. Suspension retroactive to November 25, 2018.

Technicians
Diana Altamirano (T028623) – Consent agreement for civil penalty. The consent agreement includes a $250 civil penalty.
Haleigh Lisette Enriquez (T055703) – Consent agreement for civil penalty. The consent agreement includes a $250 civil penalty.
Lauren Renee Briggs (T033343) – Consent agreement and order for surrender. License surrendered.
Rocio Loya (T059052) – Consent agreement and order for surrender. License surrendered.
Paul Palacios (T054643) – Consent agreement for civil penalty. The consent agreement includes a $250 civil penalty.
Vanessa Sue Bautista (T057865) – Decision and order. License revoked.
Michael Joseph Baker (T009273) – Decision and order. License revoked.
Deborah May Cottle (T004776) – Consent agreement for civil penalty. The consent agreement includes a $500 civil penalty.
Rocko Reynaldo Herrera (T055936) – Consent agreement and order for surrender. License surrendered.
Anakare Gonzalez (T058189) – Consent agreement for civil penalty. The consent agreement includes a $250 civil penalty.
Gilbert Edward Ramirez (T033881) – Consent agreement for civil penalty. The consent agreement includes a $250 civil penalty.
Amberly Ann Autumn Cadieux (T045153) – Consent agreement for voluntary surrender and denial of application. Technician trainee license voluntarily surrendered. Technician license application denied.
**FDA Changes Opioid Labeling to Give Providers Better Information on Tapering**

Noting that the agency remains focused on striking the right balance between policies that reduce the rates of opioid addiction while still allowing patients and health care providers access to appropriate pain treatments, Food and Drug Administration (FDA) has announced required changes to the prescribing information for all opioid analgesic medications used in the outpatient setting. The changes, announced in a Drug Safety Communication, provide expanded information to health care providers on how to safely decrease the dose in patients who are physically dependent on opioids. FDA intends for this information to be used when health care providers and patients have decided together that a decrease in dose or discontinuation of opioids is appropriate.

“Rapid discontinuation can result in uncontrolled pain or withdrawal symptoms. In turn, these symptoms can lead patients to seek other sources of opioid pain medicines, which may be confused with drug-seeking for abuse,” the agency said in the communication. “Patients may attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.”

In addition to these changes, an FDA press release also announced that additional policies related to the opioid crisis are forthcoming. These include a requirement for immediate-release formulations of opioids to be made available in fixed-quantity packaging that contain doses more typical of what patients may need for common acute pain conditions and procedures. The full press release is available in the News and Events section of the FDA website.

**DEA Warns of Scam Calls Targeting Pharmacists and Other DEA-Registered Providers**

Health care providers and other members of the public have reported receiving phone calls from people claiming to represent Drug Enforcement Administration (DEA), and threatening legal action against them if a large fine is not paid immediately over the phone. According to a DEA press release, this scam used fake names and badge numbers, or the names of well-known senior officials with DEA, and threatened victims with arrest, prosecution, imprisonment, and revocation of their DEA numbers. The agency emphasizes that DEA will never contact practitioners by phone to demand money or any form of payment. DEA will not request any personal or sensitive information by phone, and notification of legitimate investigation or legal action is made via official letter or in person.

DEA asks anyone who receives a call from a person purporting to be a DEA special agent or other law enforcement official asking for money to refuse the demand and report the threat using the online form or by calling 877/792-2873. Reporting these calls will assist DEA in investigating and stopping this activity.

**FDA Officials Outline 2019 Efforts to Improve Quality of Compounded Drugs**

Recognizing the important roles compounded drugs can play in patient care, FDA plans to continue its efforts to improve the quality of compounded drugs. According to a statement posted to the FDA website, these priorities include:

- maintaining quality manufacturing compliance,
- strengthening and refining regulations on compounding from bulk drug substances,
- finalizing the agency’s memorandum of understanding with the states, and
- issuing revised draft guidance for compounding by hospital and health systems.

“We’ve worked to refine our existing practices, shape new policies and increase the frequency of our communications with industry, Congress, states and patients concerning our programs,” then-Commissioner Scott Gottlieb, MD, and Deputy Commissioner Anna Abram said in a statement published on the FDA website. “We anticipate that 2019 will be an equally productive year for the FDA’s compounding program, with better quality continuing to be our top priority as part of our ongoing effort . . . to improve the quality of compounded products for consumers . . .”

In addition, Gottlieb and Abram’s statement notes that the agency will continue to work closely with stakeholders on these steps and any other compounding-related measures not outlined in the statement.
China Agrees to Stricter Fentanyl Production Laws Following Pressure From US Lawmakers

China has announced that all variations of the powerful opioid product, fentanyl, will be treated as controlled substances (CS). According to a press release from Senator Tom Cotton, the announcement came after a bipartisan group of United States lawmakers, including Cotton, introduced Senate Bill 1044, a bill designed to apply pressure to the Chinese government to make all forms of synthetic opioids illegal and to provide US law enforcement with more tools and resources to go after illicit traffickers in China, Mexico, and other countries.

“Combating the flow of illicit fentanyl into our country is imperative in the fight to save American lives from the opioid crisis,” Senate Minority Leader Chuck Schumer said in the press release. “We must hold China accountable for their role in the fentanyl trade. China’s new regulation to make all fentanyl categories illegal is an important step and the administration deserves praise for their efforts to secure this change. However, we have to demonstrate that we will demand China enforce these laws and take strong action against opioid traffickers.”

In a December meeting with President Donald Trump, China’s President Xi Jinping promised to classify fentanyl as a CS following a 2018 report by the US-China Economic and Security Review Commission that found China to be “the largest source of illicit fentanyl and fentanyl-like substances” in the US, according to a report from NPR. The latest increase in opioid-related overdose deaths has been largely attributed to the availability of illegally manufactured fentanyl.

Two Lots of Transdermal Fentanyl Patches Recalled Due to Product Mislabling

Alvogen, Inc, of Pine Brook, NJ, is recalling two lots of Fentanyl Transdermal System 12 mcg/h transdermal patches to the consumer level after a small number of cartons were found to contain 50 mcg/h patches. Though the 50 mcg/h patches are individually labeled correctly, accidental application of the higher dosage patch instead of the prescribed 12 mcg/h patch could result in serious, life-threatening, or fatal respiratory depression. The company has not received any reports of adverse events related to this issue.

The company is notifying its distributors and direct customers by certified letter and is arranging for the return and replacement of all recalled products. Pharmacies are asked to stop dispensing any product subject to the recall. Consumers that have affected products should immediately remove any patch currently in use and contact their health care provider. Patients with unused product should return it to the point of purchase for replacement.

Additional information on the recall, including the affected lot numbers and customer service contact information, is available in a press release posted to the FDA website. Adverse reactions and quality problems can be reported to the FDA MedWatch Safety Information and Adverse Event Reporting Program.

FDA Releases Toolkit to Help Promote Safe Opioid Disposal

FDA has made a new resource available for consumers and health care providers to help promote and educate individuals about how to safely dispose of unused opioids. The free Safe Opioid Disposal – Remove the Risk Outreach Toolkit includes video, radio, and print public service announcements, social media graphics and posts, fact sheets, drop-in content, and website badges that health care providers and other interested individuals and organizations can use to promote the message of opioid safety. The toolkit and its resources can be accessed on the Ensuring Safe Use of Medicine section of the FDA website.

An additional resource available to help consumers find disposal kiosks available year round is the National Association of Boards of Pharmacy® (NABP®) Drug Disposal Locator Tool, available in the AWARxE® Prescription Drug Safety section of the NABP website, www.nabp.pharmacy/initiatives/AWARxE. With more than 6,500 disposal sites in the continually updated database, consumers can enter location information to find the nearest disposal sites to them using a map.

Additional information about the FDA campaign can be found at https://www.fda.gov/drugs/buying-using-medicine-safely/ensuring-safe-use-medicine.
Continued from page 1

Daniel Brandon Medina (T057046) – Consent agreement and order for civil penalty. The consent agreement includes a $100 civil penalty.

Elizabeth Lopez (T033349) – Consent agreement and order for voluntary surrender. License surrendered.

Kiana M. Nash (T064770) – Consent agreement for civil penalty. License issued after $250 civil penalty paid.

Mayra E. Vazquez (T064019) – Consent agreement for civil penalty. The consent agreement includes a $300 civil penalty.

Nathan Ryan Stenzel (T037660) – Consent agreement for civil penalty. The consent agreement includes a $250 civil penalty.

Victoria Gabaldon (T001380) – Consent agreement for civil penalty. The consent agreement includes a $300 civil penalty.

Yvette Angie Gonzalez (T065035) – Consent agreement for civil penalty. License issued after $250 civil penalty paid.

Gumesinda Sauceda (T005640) – Consent agreement for civil penalty. The consent agreement includes a $150 civil penalty, 30 hours of CE required during the next renewal period, and a mandatory audit.

Marco Antonio Toscano (T065114) – Consent agreement for civil penalty. License issued after $300 civil penalty paid.

Kassidy Mowry (T053399) – Consent agreement and order for voluntary surrender. License surrendered.

Interns

Colin Gerber (I011780) – Interim consent agreement and order for voluntary surrender of license. License surrendered.

Victor Emmanuel De Dios (I013015) – Consent agreement for civil penalty. The consent agreement includes a $500 civil penalty.

Permits

Walgreens #12334 (Y005221) – Consent agreement for civil penalty. The consent agreement includes a $1,500 civil penalty.

Genoa Healthcare, LLC (Y007067) – Consent agreement for civil penalty. The consent agreement includes a $500 civil penalty.

BGH Pharmacy (Y006953) – Consent agreement for civil penalty. The consent agreement includes a $1,000 civil penalty.

MedOne Healthcare (Y007986) – Consent agreement for civil penalty. The consent agreement includes a $100 civil penalty.

Holistic Healthcare dba Greenway Tantra Drugstore (Y005773) – Consent agreement for civil penalty. The consent agreement includes a $1,000 civil penalty.

Safeway Pharmacy #1747 (Y006173) – Consent agreement for civil penalty. The consent agreement includes a $2,000 civil penalty.

Safeway Pharmacy #1604 (Y006199) – Consent agreement for civil penalty. The consent agreement includes a $1,500 civil penalty.

Application Status Updates

Danielle L. Mehrhoff-Moore – Application for licensure as a pharmacy technician denied.

Markie Lynn Lulay – Application for licensure as a pharmacy technician denied.

Disciplinary Actions and Updates – Other Health Boards

Arizona Medical Board

Terrence J. Adam, MD #33382 – Interim practice limitation (non-disciplinary). Physician is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until he applies to the Board and receives its affirmative permission to do so.

Paul A. Aupperle, MD #30485 – Request for license inactivation with cause and order inactivating license with cause. Effective May 24, 2019.

Jujhar S. Bains, MD #54547 – Interim practice limitation (non-disciplinary). Physician is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until he applies to the Board and receives its affirmative permission to do so.

James C. Barsz, MD #12365 – Interim practice restriction. Respondent is prohibited from prescribing controlled substances (CS) in the state of Arizona pending the outcome of a formal interview or formal hearing in this matter. Respondent may request, in writing, release and/or modification of this interim consent agreement. The executive director, in consultation and agreement with the lead Board member and the chief medical consultant, has the discretion to determine whether it is appropriate to release respondent from the interim consent agreement.

Napoleon R. Bravo, MD #42672 – Interim practice restriction. Respondent is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until respondent applies to the executive director and receives permission to do so.

Steven Cohen, MD #28261 – Interim practice restriction. Respondent is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until respondent applies to the executive director and receives permission to do so.

Sharron Jones-Daggett, MD #47737 – Interim practice limitation (non-disciplinary). Physician is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until she applies to the Board and receives its affirmative permission to do so.

Salim O. Dada, MD #51630 – Surrender of license effective March 8, 2019.

Karnail S. Dhillon, MD #27921 – Respondent is restricted in that he is prohibited from prescribing CS until he has completed the required continuing medical education, enters into an agreement with a Board-approved monitor to conduct chart reviews, and provides satisfactory proof of compliance with these requirements. Effective February 5, 2019.

Sean P. Elliott, MD #27986 – Interim practice restriction. Respondent is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until respondent applies to the executive director and receives permission to do so.

Susan B. Greger, MD #47822 – Interim practice restriction. Respondent is prohibited from practicing medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until she applies to the Board and receives permission to do so.

Napoleon R. Bravo, MD #42672 – Interim practice restriction. Respondent is prohibited from prescribing controlled substances (CS) in the state of Arizona pending the outcome of a formal interview or formal hearing in this matter. Respondent may request, in writing, release and/or modification of this interim consent agreement. The executive director, in consultation and agreement with the lead Board member and the chief medical consultant, has the discretion to determine whether it is appropriate to release respondent from the interim consent agreement.

Napoleon R. Bravo, MD #42672 – Interim practice restriction. Respondent is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until respondent applies to the executive director and receives permission to do so.

Sharron Jones-Daggett, MD #47737 – Interim practice limitation (non-disciplinary). Physician is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until she applies to the Board and receives its affirmative permission to do so.


Skye C. King, MD #R75477 – Surrender of license effective March 8, 2019.

Eun M. Lee, MD #29485 – Interim practice restriction. Respondent is prohibited from examining or treating female patients in all settings, including but not limited to hospital, office, and clinic settings until respondent applies to the executive director and receives permission to do so.

Ming-Jai Liu, MD #47701 – Interim practice restriction. Respondent is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until respondent applies to the executive director and receives permission to do so.

Kang Lu, MD #45528 – Respondent’s license to practice allopathic medicine in Arizona is summarily suspended in that respondent is prohibited from practicing medicine in the state of Arizona and is prohibited from prescribing any form of treatment, including prescription medications or injections of any kind.

Continued on page 5
Cedric W. McClinton, MD #12711 – Interim practice restriction. Respondent is prohibited from prescribing CS in the state of Arizona pending the outcome of a formal interview or formal hearing in this matter. Respondent may request, in writing, release and/or modification of this interim consent agreement. The executive director, in consultation and agreement with the lead Board member and the chief medical consultant, has the discretion to determine whether it is appropriate to release respondent from the interim consent agreement.

Divyesh G. Mehta, MD #30158 – Surrender of license effective April 17, 2019.

John W. Molina, MD #20789 – Physician’s practice is limited in that he shall not practice medicine in the state of Arizona and is prohibited from prescribing any form of treatment, including prescription medications, until physician applies to the Board and receives permission to do so. Effective April 16, 2019.

Michael D. Moran, MD #54854 – Interim practice restriction. Respondent is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until respondent applies to the executive director and receives permission to do so.

Steven B. Moss, PA #4818 – Surrender of license effective May 29, 2019.

Rogelio D. Naranja, MD #13156 – Surrender of license effective December 5, 2018.

David E. Nielsen, MD #54814 – Interim practice limitation (non-disciplinary). Physician is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until he applies to the Board and receives its affirmative permission to do so.

Manish J. Patel, MD #29685 – Interim practice restriction. Respondent is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until respondent applies to the executive director and receives permission to do so.

Richard M. Roberts, MD #54596 – Interim practice restriction. Respondent is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until respondent applies to the executive director and receives permission to do so.

Ava Rose, MD #50321 – Interim practice restriction. Respondent is prohibited from prescribing CS in the state of Arizona until she requests release or modification from this order.

David A. Ruben, MD #11382 – Surrender of license effective April 16, 2019.

James M. C. Ryan, MD #53075 – Respondent’s license to practice allopathic medicine in Arizona is summarily suspended in that respondent is prohibited from practicing medicine in the state of Arizona and is prohibited from prescribing any form of treatment, including prescription medications or injections of any kind.

Marvin C. Schneider, MD #4036 – Surrender of license effective January 11, 2019.

John J. Sears, MD #27392 – Surrender of license effective April 16, 2019.

Subodh S. Shroff, MD #37588 – Surrender of license effective February 5, 2019.

Gary S. Simmonds, MD #23958 – Request for license inactivation with cause and order inactivating license with cause. Effective March 21, 2019.


Lisa A. Sparks, MD #13545 – Interim practice restriction. Respondent is prohibited from prescribing CS in the state of Arizona until she requests release or modification from this order.

Roman C. Stedman, MD #R76163 – Interim practice restriction. Respondent is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until respondent applies to the executive director and receives permission to do so.

Murali D. Talluri, MD #19237 – Interim practice restriction. Respondent is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until respondent applies to the executive director and receives permission to do so.

Craig W. Tolleson, MD #36928 – Revocation of license effective February 15, 2019.

Jill R. Utley, MD #42779 – Interim practice limitation (non-disciplinary). Physician is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until she applies to the Board and receives its affirmative permission to do so.

Helen E. Watt, MD #22016 – Interim practice restriction. Respondent is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-1401 (22) until he applies to the Board and receives its affirmative permission to do so.

Arizona Naturopathic Physicians Medical Board

Michael Miller, ND #12-1313 – Surrender of license effective November 6, 2018.

Arizona Regulatory Board of P hysician Assistants

Brian Arno Cody, PA #2142 – Interim practice limitation (non-disciplinary). Respondent is prohibited from engaging in the practice of medicine in the state of Arizona as set forth in A.R.S. §32-2501 (13) until he applies to the Board’s executive director and receives its affirmative permission to do so. Respondent may not apply for relief from this practice limitation until he has completed any current treatment program, has been found safe to perform health care tasks, and the Board is in receipt of any discharge report and recommendations for aftercare. This order supersedes any previous interim practice limitation.

Todd A. Stirling, PA #5081 – Interim practice restriction. Respondent is prohibited from engaging in health care tasks with physician supervision in the state of Arizona as set forth in A.R.S. §32-2501 (13) until he applies to the executive director and receives permission to do so.

Page 5 – July 2019

The Arizona State Board of Pharmacy News is published by the Arizona State Board of Pharmacy and the National Association of Boards of Pharmacy Foundation® (NABPF®) to promote compliance of pharmacy and drug law. The opinions and views expressed in this publication do not necessarily reflect the official views, opinions, or policies of NABPF or the Board unless expressly so stated.

Kamlesh “Kam” Gandhi, PharmD - State News Editor
Carmen A. Catizone, MS, RPh, DPh - National News Editor & Executive Editor
Amy Sanchez - Communications Manager